Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

被引:0
|
作者
Cole, Frances M. [1 ]
Laszlo, George S. [2 ]
Lunn-Halbert, Margaret C. [1 ]
Kehret, Allie R. [1 ]
Zweidler-McKay, Patrick A. [3 ]
Rodriguez-Arboli, Eduardo [1 ,4 ]
Wu, David [5 ]
Nyberg, Kyle E. [1 ]
Li, Junyang [1 ]
Lim, Sheryl Y. T. [1 ]
Lakshmikanthan, Sribalaji [3 ]
Walter, Roland B. [6 ,7 ,8 ]
机构
[1] Fred Hutchinson Canc Ctr, Translat Sci & Therapeut Div, Seattle, WA USA
[2] Fred Hutchinson Canc Ctr, 1100 Fairview Ave North, Seattle, WA USA
[3] ImmunoGen Inc, Waltham, MA USA
[4] Univ Seville, Hosp Univ Virgen del Rocio, Dept Hematol, Inst Biomed Sevilla, Seville, Spain
[5] Univ Washington, Hematopathol, Seattle, WA USA
[6] Fred Hutchinson Canc Ctr, Seattle, WA USA
[7] Univ Washington, Dept Med, Div Hematol & Oncol, Seattle, WA USA
[8] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA
关键词
D O I
10.1182/blood-2024-200907
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2751 / 2751
页数:1
相关论文
共 50 条
  • [21] Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Daver, Naval
    Montesinos, Pau
    Aribi, Ahmed
    Marconi, Giovanni
    Altman, Jessica K.
    Wang, Eunice S.
    Roboz, Gail J.
    Burke, Patrick W.
    Gaidano, Gianluca
    Walter, Roland B.
    Thomas, Xavier
    Jeyakumar, Deepa
    DeAngelo, Daniel J.
    Erba, Harry P.
    Todisco, Elisabetta
    Begna, Kebede H.
    Advani, Anjali
    Gastaud, Lauris
    De la Fuente, Adolfo
    Curti, Antonio
    Mendez, Lourdes M.
    Vyas, Paresh
    Boissel, Nicolas
    Vey, Norbert
    Recher, Christian
    Longval, Thomas
    Platzbecker, Uwe
    Kapp-Schwoerer, Silke
    Schliemann, Christoph
    Konopleva, Marina
    Torres, Laura
    Sallman, David A.
    Marcucci, Guido
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Kantarjian, Hagop
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Sweet, Kendra
    BLOOD, 2022, 140
  • [22] IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
    Adams, Sharlene
    Wilhelm, Alan
    Harvey, Lauren
    Bai, Chen
    Yoder, Nicholas
    Kovtun, Yelena
    Chittenden, Thomas
    Pinkas, Jan
    BLOOD, 2016, 128 (22)
  • [23] Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)
    Han, Yoon-Chi
    Jiang, Fan
    Piche-Nicholas, Nicole
    Katragadda, Madan
    Prashad, Nadira
    Charati, Manoj
    Hu, Wendy
    Leal, Mauricio
    Tumey, Nathan
    Maderna, Andreas
    Dushin, Russell
    Kim, Kenny
    Lemon, LuAnna
    Damelin, Marc
    Gerber, H. P.
    Tchistiakova, Lioudmila
    Loganza, Frank
    O'Donnell, Chris
    Sapra, Puja
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Todisco, Elisabetta
    Lane, Andrew A.
    Acuna-Cruz, Evelyn
    Deconinck, Eric
    Wang, Eunice S.
    Sweet, Kendra L.
    Rizzieri, David A.
    Mazzarella, Luca
    DeAngelo, Daniel J.
    Montesinos, Pau
    Tarella, Corrado
    Erba, Harry P.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Daver, Naval
    BLOOD, 2020, 136
  • [25] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
    Daver, Naval G.
    Erba, Harry P.
    Papadantonakis, Nikolaos
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [26] Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
    Daver, Naval
    Montesinos, Pau
    Aribi, Ahmed
    Martinelli, Giovanni
    Altman, Jessica K.
    Wang, Eunice S.
    Roboz, Gail J.
    Burke, Patrick W.
    Gaidano, Gianluca
    Walter, Roland B.
    Thomas, Xavier
    Jeyakumar, Deepa
    DeAngelo, Daniel J.
    Erba, Harry P.
    Todisco, Elisabetta
    Begna, Kebede
    Advani, Anjali
    Gastaud, Lauris
    de la Fuente, Adolfo
    Curti, Antonio
    Mendez, Lourdes M.
    Vyas, Paresh
    Boissel, Nicolas
    Vey, Norbert
    Recher, Christian
    Longval, Thomas
    Platzbecker, Uwe
    Kapp-Schworer, Silke
    Schliemann, Christoph
    Konopleva, Marina
    Torres, Laura
    Sallman, David A.
    Marcucci, Guido
    Marconi, Giovanni
    Kantarjian, Hagop
    Sloss, Callum M.
    Malcolm, Karen E.
    Zweidler-McKay, Patrick A.
    Sweet, Kendra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S231 - S232
  • [27] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Daver, Naval G.
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Deconinck, Eric
    Erba, Harry P.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David A.
    Sweet, Kendra L.
    Martinelli, Giovanni
    Tarella, Corrado
    Todisco, Elisabetta
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [28] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
    Daver, Naval Guastad
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Todisco, Elisabetta
    Tarella, Corrado
    Martinelli, Giovanni
    Erba, Harry Paul
    Deconinck, Eric
    Sweet, Kendra L.
    Walter, Roland B.
    Levy, Moshe Yair
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David
    Konopleva, Marina
    Sloss, Callum Mortimer
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models
    Kuruvilla, Vinitha Mary
    Zhang, Qi
    Daver, Naval
    Watkins, Krystal
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Romanelli, Angela
    Konopleva, Marina
    BLOOD, 2020, 136
  • [30] Characterization of SGN-CD123A, APotent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia
    Li, Fu
    Sutherland, May Kung
    Yu, Changpu
    Walter, Roland B.
    Westendorf, Lori
    Valliere-Douglass, John
    Pan, Lucy
    Cronkite, Ashley
    Sussman, Django
    Klussman, Kerry
    Ulrich, Michelle
    Anderson, Martha E.
    Stone, Ivan J.
    Zeng, Weiping
    Jonas, Mechthild
    Lewis, Timothy S.
    Goswami, Maitrayee
    Wang, Sa A.
    Senter, Peter D.
    Law, Che-Leung
    Feldman, Eric J.
    Benjamin, Dennis R.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (02) : 554 - 564